Foundation for the National Institutes of Health
18
5
5
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
11%
1 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Role: collaborator
ASSESS ALL ALS Study
Role: collaborator
PREVENT ALL ALS Study
Role: collaborator
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
Role: lead
Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer
Role: collaborator
Noninvasive Biomarkers of Metabolic Liver Disease 1.1
Role: collaborator
Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2
Role: collaborator
Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans
Role: collaborator
Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM
Role: lead
Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development
Role: lead
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
Role: lead
Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus
Role: lead
Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis
Role: lead
ADNI: Alzheimer's Disease Neuroimaging Initiative
Role: collaborator
Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes
Role: lead
Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus
Role: lead
Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects
Role: lead
Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection
Role: collaborator
All 18 trials loaded